Login / Signup

Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live‑video randomized control trial.

Jonathan GreenbergSarah CarterEthan LesterChristopher J FunesEric A MacklinScott PlotkinChristopher J Funes
Published in: Journal of neuro-oncology (2019)
The d3RP-NF2 sustainably improves multiple dimensions of resiliency. Promoting resiliency may be of utmost importance for this uderserved population.
Keyphrases
  • hearing loss
  • double blind
  • open label
  • signaling pathway
  • placebo controlled
  • early onset
  • pi k akt
  • clinical trial
  • randomized controlled trial
  • drug induced
  • immune response
  • inflammatory response
  • toll like receptor